SMi Group announces the 10th Annual RNA Therapeutics Conference

SMi Group20 - 21 February 2019, London, UK.
Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.

Join the 10th Annual RNA Therapeutics Conference in February 2019, for SMi's 10th annual sell out event. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.

Network and learn from key opinion leaders such as:

Chairs for 2019

  • Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
  • Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

Guest Speakers

  • Carsten Rudolf, Chief Executive Officer, EthrisGmbh
  • Paul Agris, Founder and Director, The RNA Institute

Keynote Speakers

  • Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
  • David Giljohan, CEO, Exicure
  • Ingmar Hoerr, Founder & CEO, CureVac AG
  • David Blakey, Chief Scientific Officer, MiNA Therapeutics
  • André Gerber, Professor of RNA Biology, University of Surrey
  • Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
  • Markus Mandler, Chief Scientific Officer, Accanis Biotech
  • Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
  • Hans Kistemaker, Associate Director, ProQR

2019 Featured Highlights

  • Discover the clinical progress of Spherical Nucleic Acids at Exicure
  • Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
  • Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
  • Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
  • Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

For further information and to register, please visit:
http://www.therapeutics-rna.com/wpn

Early-Bird Rates

  • Register by 31st October and save £400
  • Register by 30th November and save £200
  • Register by 15th December and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...